The Endocannabinoid System and its Modulation by Phytocannabinoids

The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ9-tetrahydrocannabinol (but not for most other plant cannabinoids or phytocannabinoids)—cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R); their two most studied endogenous ligands, the “endocannabinoids” N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and the enzymes responsible for endocannabinoid metabolism. However, anandamide and 2-AG, and also the phytocannabinoids, have more molecular targets than just CB1R and CB2R. Furthermore, the endocannabinoids, like most other lipid mediators, have more than just one set of biosynthetic and degrading pathways and enzymes, which they often share with “endocannabinoid-like” mediators that may or may not interact with the same proteins as Δ9-tetrahydrocannabinol and other phytocannabinoids. In some cases, these degrading pathways and enzymes lead to molecules that are not inactive and instead interact with other receptors. Finally, some of the metabolic enzymes may also participate in the chemical modification of molecules that have very little to do with endocannabinoid and cannabinoid targets. Here, we review the whole world of ligands, receptors, and enzymes, a true “endocannabinoidome”, discovered after the cloning of CB1R and CB2R and the identification of anandamide and 2-AG, and its interactions with phytocannabinoids.

[1]  L. Petrocellis,et al.  An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. , 1998, European journal of pharmacology.

[2]  M. Cascio,et al.  The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice , 2010, British journal of pharmacology.

[3]  A. Akopian,et al.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. , 2009, Trends in pharmacological sciences.

[4]  L. Petrocellis,et al.  Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels , 2010, Journal of Neuroimmune Pharmacology.

[5]  L. Petrocellis,et al.  Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation , 2012, Acta physiologica.

[6]  D. Ponde,et al.  Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide , 2001, British journal of pharmacology.

[7]  M. Abood,et al.  GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. , 2013, Life sciences.

[8]  A. Kambalyal,et al.  Endocannabinoids Anandamide and 2-Arachidonoylglycerol Are Substrates for Human CYP2J2 Epoxygenase , 2014, Journal of Pharmacology and Experimental Therapeutics.

[9]  V. D. M. A. L. D. Petrocellis Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010 .

[10]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[11]  L. Steardo,et al.  Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement , 2014, Phytotherapy research : PTR.

[12]  V. Vellani,et al.  Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[13]  L. Petrocellis,et al.  Why do cannabinoid receptors have more than one endogenous ligand? , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[14]  R. Pertwee,et al.  Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist , 2005, British journal of pharmacology.

[15]  V. Di Marzo,et al.  Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review , 2015, British journal of pharmacology.

[16]  J. Walker,et al.  Regulation of anandamide tissue levels by N-arachidonylglycine. , 2002, Biochemical pharmacology.

[17]  D. Kendall,et al.  Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors , 2004, British journal of pharmacology.

[18]  S. Popoff,et al.  The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55 , 2012, Journal of Neuroimmune Pharmacology.

[19]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[20]  L. Petrocellis,et al.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. , 2001, The Biochemical journal.

[21]  Atsushi Inoue,et al.  Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. , 2006, Biochemical and biophysical research communications.

[22]  I. Yamamoto,et al.  Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis , 2008, Drug Metabolism and Disposition.

[23]  A. Eschalier,et al.  Monoacylglycerols Activate TRPV1 – A Link between Phospholipase C and TRPV1 , 2013, PloS one.

[24]  S. Petrosino,et al.  The anti‐inflammatory mediator palmitoylethanolamide enhances the levels of 2‐arachidonoyl‐glycerol and potentiates its actions at TRPV1 cation channels , 2016, British journal of pharmacology.

[25]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[26]  M. Hellmich,et al.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia , 2012, Translational Psychiatry.

[27]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[28]  T. Hutchinson,et al.  TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons , 2008, The Journal of Neuroscience.

[29]  B. Watkins,et al.  The endocannabinoid system: directing eating behavior and macronutrient metabolism , 2015, Front. Psychol..

[30]  C. Russo,et al.  Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide , 2013, British journal of pharmacology.

[31]  H. Bradshaw,et al.  The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways , 2009, BMC Biochemistry.

[32]  B. Birnir,et al.  Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists* , 2005, Journal of Biological Chemistry.

[33]  Benjamin J. Whalley,et al.  Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. , 2014, ACS chemical neuroscience.

[34]  A. Saghatelian,et al.  A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. , 2006, Biochemistry.

[35]  Stephen P. H. Alexander Common Receptors for Endocannabinoid-Like Mediators and Plant Cannabinoids , 2015 .

[36]  S. O'Sullivan,et al.  Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.

[37]  K. Mackie,et al.  Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. , 1995, Molecular pharmacology.

[38]  Stephen P. H. Alexander,et al.  Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. , 2007, British journal of pharmacology.

[39]  M. Cascio,et al.  New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. , 2007, Journal of medicinal chemistry.

[40]  E. Brǎiloiu,et al.  Activation of GPR18 by cannabinoid compounds: a tale of biased agonism , 2014, British journal of pharmacology.

[41]  M. Correia,et al.  Characterization of cannabidiol-mediated cytochrome P450 inactivation. , 1993, Biochemical pharmacology.

[42]  K. Verhoeckx,et al.  Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. , 2011, Biochimica et biophysica acta.

[43]  J. Lanciego,et al.  CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum , 2014, Experimental Neurology.

[44]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[45]  V. Di Marzo,et al.  Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors , 2001, FEBS letters.

[46]  Pierangelo Geppetti,et al.  An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Renger,et al.  Cross-Modulation and Molecular Interaction at the Cav3.3 Protein between the Endogenous Lipids and the T-Type Calcium Channel Antagonist TTA-A2. , 2014, Molecular Pharmacology.

[48]  M. Connor,et al.  Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol* , 2008, Journal of Biological Chemistry.

[49]  Marc G Caron,et al.  Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands* , 2009, The Journal of Biological Chemistry.

[50]  L. Steardo,et al.  Effect of cannabidiol on sepsis‐induced motility disturbances in mice: involvement of CB1 receptors and fatty acid amide hydrolase , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[51]  G. Ahern Activation of TRPV1 by the Satiety Factor Oleoylethanolamide* , 2003, Journal of Biological Chemistry.

[52]  R. Pertwee The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. , 2008, British journal of pharmacology.

[53]  T. Bisogno,et al.  Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes* , 1997, The Journal of Biological Chemistry.

[54]  V. Di Marzo,et al.  Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010, Current medicinal chemistry.

[55]  L. Petrocellis,et al.  Fifty years of ‘cannabinoid research’ and the need for a new nomenclature , 2014 .

[56]  T. Bisogno,et al.  Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.

[57]  T. Bisogno,et al.  Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.

[58]  V. Di Marzo,et al.  Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. , 2007, Experimental cell research.

[59]  Stephen P. H. Alexander,et al.  Cannabinoid activation of PPARα; a novel neuroprotective mechanism , 2007 .